Galapagos NV ((GLPG)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Galapagos NV is conducting a study titled ‘A Phase I/II, Multicenter Study Evaluating the Feasibility, Safety, and Efficacy of Point-of-care Manufactured GLPG5101 (19CP02) in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to determine if GLPG5101 is effective and safe for treating non-Hodgkin lymphoma, focusing on dose optimization and expansion to assess efficacy.
Intervention/Treatment: The study tests GLPG5101, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, designed to target and treat B-cell non-Hodgkin lymphoma.
Study Design: This interventional study is non-randomized with a sequential intervention model. It involves no masking and primarily aims to treat the condition by determining the optimal dose in Phase I and expanding to various cohorts in Phase II.
Study Timeline: The study began on August 16, 2024, with the latest update submitted on August 26, 2025. These dates are crucial for tracking progress and ensuring timely updates on the study’s recruitment and results.
Market Implications: The progress of this study could significantly impact Galapagos NV’s stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the oncology market. The ongoing development of GLPG5101 could represent a breakthrough in CAR T cell therapies, potentially influencing industry trends.
The study is currently recruiting, with further details available on the ClinicalTrials portal.